# (COVID-19) Longitudinal Neutralizing Antibody Titers in Cancer Patients Receiving Different Anti-caner Therapies

> **NCT05384509** · — · RECRUITING · sponsor: **Chang Gung Memorial Hospital** · enrollment: 320 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DIAGNOSTIC_TEST:** solid organ malignancies treatment

## Key facts

- **NCT ID:** NCT05384509
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-01
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-02-28
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05384509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05384509, "(COVID-19) Longitudinal Neutralizing Antibody Titers in Cancer Patients Receiving Different Anti-caner Therapies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05384509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*